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Abstract
Background: Inpatient hyperglycaemia and diabetes mellitus (DM) are common and are associated with an
increased risk of complications and mortality. The severity of hyperglycaemia determines the rate of complications
in patients treated in the emergency department (ED). Our aim was to examine whether determination of the
capillary haemoglobin A1c (HbA1c) is a reliable method for detecting unknown diabetes and poor glycaemic
control in the ED.
Methods: A prospective observational study was conducted in adult (>18 years) patients treated in a single-centre
ED. We compared the results of HbA1c levels measured by Bio-Rad in2it point-of-care device on a capillary blood
sample and by the hospital laboratory.
Results: A total of 187 ED patients with an average age of 57.1 ± 19.2 years were studied. The mean HbA1c value was
5.78 ± 1.26 % by capillary POC testing and 6.10 ± 1.12 % by the hospital laboratory (correlation = 0.712, P < 0.001). A
total of 17.1 % of cases had a prior diagnosis of DM. The diagnosis of DM (plasma glucose > 126 mg/dL and/or
HbA1c > 6.5 %) was made in ten (5.4 %) additional cases (prior undiagnosed DM) for a total prior DM prevalence of
22.5 % (95 % CI 16.4–28.5 %). Capillary HbA1c detected 11 additional cases of unknown DM (5.9 %). A capillary HbA1c
value greater than 6 % has a sensitivity of 85.7 % and specificity of 85.3 % for the screening of DM.
Conclusions: Determination of the capillary HbA1c in the ED is a reliable, fast, and simple system for the screening of
unknown or uncontrolled DM.
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Background
Hyperglycaemia is a risk marker of morbidity and mor-
tality in the emergency department (ED) and subsequent
hospital admission, both in people with and without a
history of diabetes mellitus (DM) [1–4]. Detection and
management of hyperglycaemia in the ED, however, re-
mains insufficient [5]. Hospital and ED admissions could
become windows of opportunity for an early diagnosis of
people with diabetes and for improving glycaemic control.
Providing information on previous glycaemic control of
patients treated in the ED can be useful for stratifying a
risk of complications and in tailoring antidiabetic
treatment.
Determination of the glycated haemoglobin A1c
(HbA1c) value is the best reference measure of gly-
caemic control in individuals with diabetes. It reflects
the glycaemic environment in the past 2 to 3 months.
International guidelines recommend measuring the
HbA1c value every 3 months in patients that are off tar-
get and/or after a therapeutic change, and two annual
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measurements should be conducted in all patients [6].
In many cases, HbA1c monitoring falls short of the rec-
ommended frequency. The HbA1c value is a major indi-
cator to start an intensified medical treatment in
patients with DM. In addition, international guidelines
have included HbA1c measurement among the methods
for diagnosis [6] (Table 1). Silverman et al. proposed
HbA1c cut-offs for screening of diabetes in the ED [7].
Using 6 % as the cut-off, the sensitivity of HbA1c was
76.9 % and the specificity was 87.3 %. Even lower HbA1c
levels (5.7 %) have been proposed as a useful tool for the
screening of prediabetes.
In recent years, several methods have become available
to quickly and easily measure HbA1c from the capillary
blood. There are several available easy-to-use point-of-
care systems that can be used in the ED. While they are
no substitutes for certified HbA1c measured by the la-
boratory to confirm the diagnosis of DM, their accuracy is
highly satisfactory for estimating the degree of control of
DM [8] and detecting undiagnosed diabetes [9] or at-risk
subjects [10]. In this study, we propose to test the useful-
ness of a point-of-care HbA1c system in the ED for the
detection of undiagnosed and poorly controlled DM.
Methods
Study design
This prospective observational study was conducted at
Nuestra Señora de Sonsoles Hospital of Ávila, Spain, a
second-level hospital with an ED that covers the needs
of a population of nearly 200,000 inhabitants, with ap-
proximately 37,000 adult ED visits annually (650 visits a
week). We obtained an institutional review board ap-
proval prior to initiation of the study.
Subjects
For seven consecutive days during 2012, informed consent
was requested from all adult individuals (over 18 years)
who were treated at the ED of Nuestra Señora de Sonsoles
Hospital of Ávila. They were asked via a questionnaire
whether they had received a prior diagnosis of diabetes.
Those that had used corticosteroids in the past 2 months
were excluded. The remaining patient’s clinical data was
obtained from medical history, including detailed verifica-
tion of the existence of a prior diagnosis of diabetes or the
result of a diagnostic biochemical tests in accordance with
the American Diabetes Association (ADA) criteria [6]
(Table 1).
A capillary blood sample was taken from all patients in
the finger pad. An Accu-Chek Aviva™ (Roche Diagnostic,
Indianapolis, IN, USA) glucometer was used for in situ
measurement of capillary blood glucose. The capillary
HbA1c value was determined in situ by an in2it™ system
(Bio-Rad, Hercules, CA, USA). Additionally, a venous
blood sample was obtained by venepuncture and was sent
to the hospital’s central laboratory for measurement of
plasma glucose and HbA1c levels.
Statistical analysis
SPSS 11.0 software was used for the statistical analysis of
the data. Correlation coefficients were estimated be-
tween and among values obtained in the ED and the la-
boratory by both the Pearson and Spearman methods
(given the asymmetries in the variables). The linear fit
was assessed by the R2 value. P values were estimated
using a one-tailed test. Diabetes diagnoses were deter-
mined in the laboratory and ED, and the sample was
stratified by age (>/<40 years). The diagnostic efficacy of
the HbA1c value and glucose level in the blood was
assessed for different cut-offs using ROC curves, and the
sensitivity, specificity, and positive and negative predict-
ive values were estimated. The degree of agreement was
established with the kappa coefficient. The relationship
was assessed with a chi-square test.
Results
Patient characteristics
A total of 187 patients that fulfilled inclusion criteria
agreed to participate and, with all data available, were
examined. Of them, 101 were men, with a median age of
64, interquartile range (IQR) of 66 years, and mean age
of 57.1 ± 19.2 years (95 % CI 54.3–59.9 years) with a
range of 18–84 years. Their demographic and clinical
data are described in Table 2.
Glucose and HbA1c
The capillary blood glucose level (mean ± SD) was
114.8 ± 44.9 (95 % CI 108.3–121.3) mg/dL. The labora-
tory blood glucose level (mean ± SD) was 117.3 ± 42.1
(95 % CI 110.9–123.7) mg/dL. The capillary HbA1c
value was 5.78 ± 1.26 % (95 % CI 5.60–5.97 %), with a
range of 4.00–12.30 %, and the laboratory level was
6.10 ± 1.12 % (95 % CI 5.94–6.26 %), with a range of
Table 1 Criteria for the diagnosis of diabetes in accordance
with the American Diabetes Association (ADA) [6]
HbA1c >6.5 %. (The test should be performed in a laboratory using a
method that is NGSP certified and standardized to the DCCT assay.)a
OR
FPG >126 mg/dL (7.0 mmol/L). (Fasting is defined as no caloric intake
for at least 8 h.)a
OR
2-h PG >200 mg/dL (11.1 mmol/L) during an OGTT. (The test should be
performed as described by the WHO, using a glucose load containing
the equivalent of 75 g anhydrous glucose dissolved in water.)a
OR
In a patient with classic symptoms of hyperglycaemia or hyperglycaemic
crisis, a random plasma glucose is >200 mg/dL (11.1 mmol/L).
DCCT Diabetes Control and Complications Trial, FPG fasting plasma glucose,
NGSP National Glycohemoglobin Standardization Program, OGTT oral glucose
tolerance test, WHO World Health Organization
aIn the absence of unequivocal hyperglycaemia, results should be confirmed
by repeat testing
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4.50–11.50 %. The correlations between the measure-
ments in the ED and laboratory were very high in both
cases (glucose: R2 = 0.739, P < 0.0001; HbA1c: R2 =
0.789, P < 0.001) and are described in Fig. 1.
Diagnosis of diabetes
Thirty-two subjects (17.1 %) stated a prior known diag-
nosis of DM. Using the 2015 ADA criteria for the diag-
nosis of DM (plasma glucose > 126 mg/dL and/or
HbA1c > 6.5 %) and previous clinical history data, ten
more cases were revealed (prior undiagnosed DM)
(5.4 %). The total number of patients who met any cri-
teria for prior DM was 42, for a 22.5 % prevalence rate
(95 % CI 16.4–28.5 %). The capillary HbA1c values
were useful in detecting 11 additional cases of
unknown DM (5.9 %).
Degree of control of prior DM
In patients with prior DM (n = 42), the HbA1c values
were >7 % (61.9 %), >8 % (28.6 %), and >9 % (16.7 %) by
the hospital laboratory and >7 % (47.6 %), >8 % (19.0 %),
and >9 % (11.9 %) by capillary testing.
Diagnostic efficacy of HbA1c and glucose levels
The ROC curve of the capillary HbA1c value measured
in the ED had an area under the curve (AUC) of 0.897
(95 % CI 0.835–0.960, P < 0.0001) (Fig. 2). Using 6 % as
the cut-off and cross-referencing with the DM diagno-
sis, we obtained a sensitivity (S) of 85.7 %, positive pre-
dictive value (PPV) of 63.2 %, specificity of 85.3 % (122
of 143), and negative predictive value (NPV) of 95.3 %
(122 of 128) (χ2 = 76.83; 1 gl; P < 0.000; kappa = 0.631).
According to coordinates of the curve, the 6 % cut-off
Table 2 Demographic, clinical, and analytical data
n = 187
Age, years (mean ± SD) 57.1 ± 19.2
Male, n (%) 101 (54)
Emergency room diagnosis, n (%)
Neurological
Stroke 6 (3.2)





Respiratory infection 16 (8.6)
Asthma 2 (1.1)
Chest pain 10 (5.3)





Biliary diseases 6 (3.2)
GB 2 (1.1)













Diabetes prevalence, n (%)
Prior known DM 32 (17.1)
Prior undiagnosed DM 10 (5.4)
Unknown DM 11 (5.9)
Total estimated DM 51 (28.5)
Capillary blood glucose in ED (mean + SD), mg/dL 114.8 ± 44.9
Laboratory blood glucose (mean + SD), mg/dL 117.3 ± 42.1
Capillary HbA1c in ED (mean + SD), % units 5.78 ± 1.26
Laboratory HbA1c (mean ± SD), % units 6.10 ± 1.12
IHD ischaemic heart disease, COPD chronic obstructive pulmonary disease, AGE
acute gastroenteritis, GB gastrointestinal bleeding, CHF chronic heart failure,
UTI urinary tract infection, SD standard deviation, HbA1c glycated haemoglobin Fig. 1 Capillary and laboratory haemoglobin A1c (HbA1c) correlation
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seemed to best balance the sensitivity and specificity,
with both greater than 85 % (Table 3). A previous study
in acutely ill patients with random hyperglycaemia at
hospital admission showed that a 6.0 % laboratory
HbA1c level was 100 % specific (14/14) and 57 % sensi-
tive for diabetes diagnosis [11].
Discussion
An early diagnosis of DM remains an unsolved chal-
lenge. Scientific data repeatedly confirm the need for an
early treatment of DM to avoid the development of
complications. However, the Di@bet.es study has shown
that the prevalence of DM in the adult Spanish popula-
tion is 13.8 %, with a distribution of 7.8 % of known DM
and 6 % of unknown DM [12]. This rate of undiagnosed
DM is clearly higher than that described in other coun-
tries [13] and highlights the importance of screening and
early detection [14]. Current guidelines recommend dia-
betes screening in adults over 45 years of age and/or those
who have a body mass index greater than 25 kg/m2 and
with any additional known risk factor for DM [6]. The rec-
ommended tests for screening are the same as those used
for diagnosis and include fasting plasma glucose (FPG),
HbA1c level, and/or an oral glucose tolerance test
(OGTT). The latter test is inconvenient, expensive, and
complex, for which it is seldom used in clinical practice.
Determination of blood glucose is limited by the influence
of multiple factors (prior intake, drugs, stress, etc.). HbA1c
measurement, although more expensive than blood
glucose determination, provides information on the gly-
caemic environment during the previous 2 to 3 months.
Several epidemiologic studies and meta-analyses have
reported that diabetes screening in the population over
40 years of age and in high-risk individuals (those with a
family history of diabetes and/or hypertension) is cost-
effective [15]. Determination of HbA1c is considered the
best test, with an intermediate cost between measuring
the FPG and the OGTT [15]. However, screening access
by HbA1c testing is limited, especially in socioeconomi-
cally deprived areas, unless it is performed at primary
care consultations [16]. Taking advantage of situations in
which people come to the hospital can be a “window of
opportunity” for the detection of DM. The population of
adults treated in the ED, as described in our sample,
would mostly belong to this high-risk group of undiag-
nosed DM patients [17]. In our sample, 22.5 % of adult
patients who were treated at the ED met the DM cri-
teria and another 5.9 % met the criteria for newly diag-
nosed DM. This finding is consistent with previous
studies [7, 18, 19]. HbA1c levels are also an indicator
of future DM and may be useful for defining personal-
ized prevention strategies [20].
Hyperglycaemia is a risk marker for hospital mortality
[1]. However, stressors and lack of fasting may influence
the interpretation of a single measurement of blood
Fig. 2 Diagnostic efficacy (sensitivity and specificity) for different
cut-off values of capillary HbA1c assessed by receiver operating
characteristic (ROC) curve (see also Table 2)
Table 3 Diagnostic efficacy (sensitivity and specificity) for
different cut-off values of capillary HbA1c assessed by receiver
operating characteristic (ROC) curve




















Diagnostic efficacy (sensitivity and specificity) for different cut-offs value of
capillary HbA1c assessed by ROC (Receiver Operating Characteristic) curve. The
best diagnostic performance is achieved with a cutoff of 6 % (marked in italics)
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glucose in the laboratory and/or ED. In addition, optimal
thresholds for DM screening in ED have not been deter-
mined. Capillary HbA1c levels in the ED can be used to
detect patients with poor glycaemic control who are at
risk of acute and chronic complications [21–23]. Among
the patients with DM who were included in our study,
47.6 % had an HbA1c value above 7 % (the accepted tar-
get of good control) and 19.0 % had clearly insufficient
DM control (over 8 %). In the entire sample, 10.8 % of
the patients showed levels above 7 % and 4.3 % had
levels higher than 8 %.
Our study indicates that measurement of HbA1c by
capillary point-of-care testing could provide considerable
advantages in the detection of DM, including immediacy
of the result, and the possibility of using the information
to guide medical treatment. Clinical practice guidelines
recognize that there are no randomized trials demon-
strating improved outcomes using HbA1c levels to assist
in the diagnosis of diabetes or to guide the glycaemic
management of inpatients with known diabetes. How-
ever, they unanimously agreed on the practical utility of
this strategy based in the consensus opinion [24]. The
issue of a possible cost reduction can be addressed by
future studies. These advantages are especially applicable
to care in an ED. HbA1c information could modify the
treatment indicated for the symptoms that brought the
patient to the ED. Additionally, in patients with both
known DM and newly diagnosed DM, capillary HbA1c
information can be useful in determining the most ap-
propriate antidiabetic treatment (i.e., use of oral agents
vs. insulin).
Major limitations of our study are the inclusion of a
single medical institution and the possibility of a selec-
tion bias. To limit this constraint, we recruited all adult
patients with no limitations other than their consent or
use of hyperglycaemic medications such as corticoste-
roids. In addition, haemoglobinopathies are a known
cause of erroneous results in determining HbA1c levels;
however, the prevalence of these diseases in our popula-
tion was very low.
Conclusions
Determination of capillary HbA1c levels in the ED is
a reliable, fast, and simple system for the detection of
unknown and poorly controlled DM. Due to the need
to improve the early detection of DM and the appro-
priate selection of antidiabetic therapy, our results
suggest that capillary HbA1c represents an important
diagnostic tool in the ED. Future studies should in-
vestigate if the use of capillary HbA1c measurement
in the ED can improve clinical outcome, reduce com-
plications, and guide treatment selection in patients
with hyperglycaemia and diabetes.
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